Classification upheld: 22 Ayurvedic medicaments under Chapter 30 entry 3003 taxed; 70 products classified as cosmetics under Chapter 33

SC affirmed Tribunal's classification: 22 products were Ayurvedic medicaments under Chapter 30 (entry for 3003) and taxed accordingly, while the remaining 70 were cosmetics under Chapter 33. The Court upheld reliance on labels, drug licences and expert opinion to determine medicinal character, held that minor therapeutic ingredients or cosmetic uses do not convert products into cosmetics, accepted the agreed valuation, and rejected Revenue's limitation argument. The Tribunal's reasoning was approved and all appeals were dismissed.

---

---

Issues Involved:
1. Classification of 22 products manufactured by IRLP.
2. Valuation of the products.
3. Applicability of the extended period of limitation.

Detailed Analysis:

1. Classification of 22 Products:

The primary issue was whether the 22 products manufactured by IRLP should be classified under Central Excise Tariff Sub-heading 3003.30 as "Ayurvedic medicines" attracting 10% duty or under Chapter 33 as "cosmetics" and "toilet preparations" attracting 40% duty. The Tribunal had earlier classified these products under Sub-heading 3003.30, a decision challenged by the Revenue.

Arguments by Revenue:
- The Revenue argued that these products were cosmetics, not Ayurvedic medicines, and should be classified under Chapter 33.
- They relied on the common parlance test and various statements and literature suggesting the products were used for beautification.

Arguments by Assessee:
- The Assessee argued that the products contained Ayurvedic medicinal herbs and were marketed as Ayurvedic medicines.
- They relied on the fact that the products were manufactured under a drugs license and were labeled as having medicinal properties.

Court's Analysis:
- The Court examined the ingredients, manufacturing licenses, and labels of the products.
- It referred to previous judgments, including BPL Pharmaceuticals Ltd. v. Collector of Central Excise, Vadodara, which distinguished between cosmetics and drugs based on their intended use and labeling.
- The Court noted that merely because a product could be used for beautification did not make it a cosmetic if it had medicinal properties and was marketed as such.
- The Court upheld the Tribunal's classification of the 22 products under Sub-heading 3003.30, except for "Bio-Heena" and "Bio Heena Leaf," which were conceded by the Assessee to be cosmetics.

2. Valuation of the Products:

The valuation issue was secondary but crucial for determining the assessable value for duty computation.

Statement by Assessee:
- The Assessee proposed that the least price charged to third parties should be taken as the basis for sales to IMPL.
- If products were sold only to IMPL, the wholesale price charged by IMPL to dealers should be the basis.
- Permissible deductions under Section 4 should be allowed.

Revenue's Position:
- The Revenue did not object to the Assessee's proposal.

Court's Decision:
- The Court accepted the Assessee's statement and held accordingly for valuation purposes.

3. Applicability of the Extended Period of Limitation:

The Tribunal had held that the extended period of limitation was not applicable, a finding challenged by the Revenue.

Arguments by Revenue:
- The Revenue sought to apply the extended period of limitation for the Show Cause Notices issued.

Arguments by Assessee:
- The Assessee argued that there was no suppression or mis-statement of facts to justify the extended period.
- They cited the case of Shahnaz Ayurvedics v. Commissioner of Central Excise, Noida, where the extended period was not applied.

Court's Analysis:
- The Court compared the products in question with those in the Shahnaz Ayurvedics case and found them comparable.
- It agreed with the Tribunal's finding that there was no suppression or mis-statement by the Assessee.
- The Court affirmed the Tribunal's decision that the extended period of limitation was not applicable.

Conclusion:
The Supreme Court dismissed the appeals by the Revenue, upholding the Tribunal's classification of the 22 products as Ayurvedic medicines under Sub-heading 3003.30, accepting the Assessee's valuation method, and affirming that the extended period of limitation was not applicable. No costs were imposed.

---